Latham & Watkins Advises Structure Therapeutics on Upsized US$650 Million Offering of ADSs and Pre‑Funded Warrants

"Latham & Watkins represented the underwriters in Structure Therapeutics Inc.'s upsized US$650 million underwritten public offering. Structure priced 8,461,538 ADSs at US$65 each and pre‑funded warrants to purchase 1,538,462 ADSs at US$64.9999. All securities were sold by Structure Therapeutics."

Latham & Watkins represented the underwriters in the transaction, while Structure Therapeutics Inc. acted as the issuer. Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical‑stage global biopharmaceutical company developing oral small molecule therapeutics for metabolic diseases with a focus on obesity, priced an upsized underwritten public offering totaling US$650 million. The offering consisted of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, offered at US$65 per ADS, together with pre‑funded warrants to purchase 1,538,462 ADSs at a price to the public of US$64.9999 per pre‑funded warrant. All of the securities in the offering were sold by Structure Therapeutics. Latham & Watkins represented the underwriters with a team composed by: San Diego partner Matt Bush (Capital Markets), counsel Anthony Gostanian (Capital Markets), and associates Rachel Staub and Madeline Hodges.

Latham & Watkins Advises Structure Therapeutics on Upsized US$650 Million Offering of ADSs and Pre‑Funded Warrants

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads